AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyCase reportPublished in a peer-reviewed journal
Clinical Improvement in Pregnant Woman with MS Following High-Potency Treatment
A case report involving a 46-year-old pregnant woman with known MS indicated that she showed clinical improvement after receiving intravenous methylprednisolone and rituximab following a rebound of symptoms from discontinuing her disease-modifying therapy.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
This finding highlights a potential treatment approach for managing MS symptoms during pregnancy, though results are limited to a single case and not broadly applicable.
What this does not prove
The case report format limits generalizability to broader populations of women with MS.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Case report
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- pregnant woman, age 46 years, with known MS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceIs Pregnancy Protective from Rebound After Fingolimod Cessation? ↗DOI: 10.3121/cmr.2026.2064
Supporting passages (8)
interventionShe was managed acutely with intravenous methylprednisolone and rituximab.
findingsFollowing high-potency treatment, the patient demonstrated clinical improvement and maintained a stable postpartum course.
populationThis case report describes a pregnant woman, age 46 years, with known MS who experienced a rebound phenomenon after abruptly stopping her DMT.
limitationsTitle: Is Pregnancy Protective from Rebound After Fingolimod Cessation?
peer reviewedPublication types: Journal Article; Case Reports
subjectsMeSH terms: Humans; Female; Fingolimod Hydrochloride; Pregnancy; Multiple Sclerosis; Pregnancy Complications; Immunosuppressive Agents; Middle Aged; Rituximab; Methylprednisolone; Recurrence; Treatment Interruption
subjectsPublication types: Journal Article; Case Reports
study designPublication types: Journal Article; Case Reports
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.